Clinical trials
High Risk Prostate Cancer clinical trials
Below are recruiting high risk prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 348 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT07255664RecruitingPhase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer
This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.
FrankfurtAges 18 years+ - NCT07276438Recruiting
Image-guided radiation therapy for localized prostate cancer
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
Los Angeles, CaliforniaAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07325721RecruitingPhase 2
Shorter radiation with a focused boost for high-risk prostate cancer
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Charleston, South CarolinaAges 18 years+ - NCT07335796RecruitingPhase 2
Testing a new drug combination before prostate cancer surgery
This trial tests a new drug (BMS-986365) combined with another hormone therapy (degarelix) before radical prostatectomy for high-risk prostate cancer. The goal is to see if this combination helps lower cancer activity before surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07343349Recruiting
Adding a higher radiation dose to prostate tumors during standard radiotherapy
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
AarhusAges 18 years+ - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT01834001Recruiting
MRI checks how prostate cancer responds to radiation
This study uses MRI scans to see how prostate cancer changes after radiation treatment, especially in the local (prostate-area) response. It may help doctors better judge treatment effectiveness and plan care more precisely.
Bethesda, MarylandAges 18–120 - NCT02016248Recruiting
Radiation “boost” for higher-risk prostate cancer
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
Fountain Valley, CaliforniaAges 18 years+ - NCT02526368RecruitingEarly Phase 1
Scan your prostate with special MRI using pyruvate to find high-grade cancer
This trial tests whether a specialized MRI scan using a pyruvate tracer can better detect high-grade (more aggressive) prostate cancer. It may help doctors find cancer more accurately and guide treatment decisions or targeted follow-up.
San Francisco, CaliforniaAges 18 years+ - NCT02543905Recruiting
Profile study for men at higher prostate cancer risk
This trial looks at how inherited risk (family history or gene findings) relates to screening and treatment for prostate cancer. If you qualify, you may be offered prostate screening tests and follow-up to see how well risk information predicts next steps.
Sutton, SurreyAges 40–69 - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07426055RecruitingPhase 2/Phase 3
Prostate cancer radiation boost comparison study
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07223385RecruitingPhase 2
Heart health check for prostate cancer patients on ARPI therapy
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Los Angeles, CaliforniaAges 45 years+ - NCT07500701RecruitingPhase 3
Comparing two radiation schedules for rising PSA after prostate surgery
This trial is testing two types of radiation therapy for men whose PSA level rises after prostate removal, but without clear signs of cancer spread on a PSMA PET scan. The goal is to see which radiation schedule works better to control the cancer.
Seoul, Gangnam-guAges 20 years+ - NCT07553780Recruiting
Tracking Prostate Cancer Response Using PSMA Imaging Scans
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
Lanzhou, GansuAges 18 years+ - NCT07562438RecruitingPhase 2
Lutetium-177 Treatment for Advanced Prostate Cancer
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Fuzhou, FujianAges 18–90 - NCT07568613Recruiting
PSMA PET/CT versus MRI for mapping prostate cancer
This trial compares two imaging techniques—PSMA PET/CT and MRI—to see which one better finds and outlines prostate cancer tumors. You'll receive both scans to help doctors understand which method works best for newly diagnosed prostate cancer.
LimassolAges 18 years+ - NCT07580196Recruiting
Comparing lymph node removal approaches in aggressive prostate cancer
This trial compares two surgical approaches for removing lymph nodes during prostate cancer surgery in men with high-risk disease on one side of the prostate. The goal is to determine whether removing lymph nodes from both sides or just one side provides better outcomes.
Rozzano, MilanoAges 18 years+ - NCT07635238RecruitingPhase 2
Lower Dose Radiation for Prostate Cancer
This trial tests whether a lower dose of radiation can effectively treat prostate cancer while reducing side effects. It is for men with certain types of prostate cancer that are visible on an MRI.
Basking Ridge, New JerseyAges 18 years+ - NCT07645391Recruiting
Early Detection Program for Men at High Genetic Risk for Prostate Cancer
This study aims to find prostate cancer early in men who have a genetic predisposition (inherited genetic mutations or strong family history) that puts them at higher risk. The goal is to detect it sooner, when treatment may be more effective.
Ann Arbor, MichiganAges 35–70
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high risk prostate cancer?
- Yes. Clin2 currently lists 348 recruiting high risk prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high risk prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high risk prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.